NEWS BRIEF
GE HealthCare’s comprehensive approach to breast cancer careWith breast cancer now surpassing lung cancer as the most commonly diagnosed cancer worldwide, clinicians are seeking tools that can address issues related to access, burnout, variability, and cost in breast imaging to not only enhance the detection and diagnosis of breast cancers, but also help improve overall patient outcomes.
Senographe Pristina™Mammography Platform:
The Senographe Pristina mammography system was designed to ease anxiety the moment the patient enters the exam room. It features an inviting gantry with elegant lighting and rounded shapes, as well as a soft-curved surface that welcomes patients into a space of comfort and support.
Today, the Senographe Pristina platform continues to evolve with the latest introduction of Pristina Via* designed to enhance the screening experience for both technologists and patients.
Pristina Via:
As the company continues to evolve the patient-centric Senographe Pristina platform, the new Pristina Via* mammography system is designed to enhance the screening experience for both technologists and patients. This innovation provides mammography technologists with a suite of sophisticated tools that balance the demands of diagnostic accuracy and fast-paced workflows to facilitate more patient-centered breast care.
The Pristina Via mammography system brings the following new features to the platform:
• Zero-click acquisition functionality for faster, seamless workflows.
• No wait time between exposures, allowing technologists to operate at their own speed. Pristina Via DBT image-to-image cycle time is up to twice as fast as other mammography systems on the market.1
• Vendor-neutral prior image comparison, reducing time spent analyzing previous exams and enabling final assessments more efficiently.
• Lowest radiation dose used for all breast thicknesses amongst major mammography systems. 2
GE HealthCare developed the Pristina Via to build on its commitment to developing innovations that are driven by people and the challenges they face.
Pristina Dueta™:
An industry-first, patient- assisted compression remote control device that gives patients a sense of control around their breast compression during a mammogram while under the supervision of a technologist to minimize their discomfort.3
SenoBright™HD Contrast Enhanced Mammography (CEM):
Performed as a follow-up to an inconclusive mammography and ultrasound, SenoBright™ HD highlights areas of unusual blood flow patterns, so practitioners can precisely see what matters. SenoBright™ HD provides advanced image quality with high specificity to help reduce false-positives and to help prevent unnecessary biopsies and surgeries. The exam can be performed in less than seven minutes – using the same mammography equipment, in the same room, with the same staff.4 Delivering clear image quality, CEM offers a high level of confidence for clinicians and patients.
Pristina Serena™ 3D Biopsy:
If medical indications recommend pathology, Pristina Serena 3D Biopsy transforms a Senographe Pristina screening room into an interventional suite in just two minutes with the dedicated add-on biopsy kit without requiring a long and mechanical needle installation. Clinicians now have the option of accessing the breast with the newly designed “side approach” to access a larger working space for ease of patient positioning, reducing needle visibility to help ease patient anxiety and allow best access to lesions close to the breast support.
Serena Bright™ Contrast-Guided Biopsy:
The industry’s first contrast-guided biopsy solution designed to biopsy lesions that are otherwise not clearly identifiable. The technology, which received U.S. Food and Drug Administration 510(k) clearance in May 2020, allows patients to have their breast biopsy exams with contrast guidance using the same mammography equipment, in the same room, and with the same staff as the screening or diagnostic mammogram.
Pristina Bright**
In an effort to help further advance breast cancer and support healthcare providers in a starting a new contrast program, GE Healthcare’s Pristina Bright** offering provides a comprehensive solution. Pristina Bright combines SenoBright™ HD, Pristina Serena™, and Serena Bright™ with an education program that includes dedicated on-site support, CME accredited self assessment, as well as access to the users’ club where providers will be able to share with experts around the globe and leverage resources needed to market their facility among referring doctors and patients.
MEDIA CONTACT
Linh Dinh Communications Director Magnetic Resonance Linh.Dinh@gehealthcare.com M: +1 408.275.5682
* Pristina Via is commercial name of Senographe Pristina.
**Pristina Bright is a commercial offering including SenoBright HD, Pristina Serena and Serena Bright
1.Image to Image cycle time is the minimum waiting time by the System between two consecutives images. Measured with ACR phantoms for Pristina Via compared to claimed performance of competitor (Dimension 3D_ in Product Data Sheet from Jul-2024)
2.Phantom measurements as of July 2024. Senographe Pristina with default value STD mode. Dose comparison based on NHS Breast Screening Programme equipment reports. https://medphys.royalsurrey.nhs.uk/nccpm/?s=technicalreports
3.5 IPSOS Patient Satisfaction Study sponsored by GE Healthcare, conducted with 315 patients across 2 sites in Europe, out of whi ch 160 were offered the patient-assisted compression option, February 2017
4. 24 Daniaux et al. Arch Gynecol Obstet , 2015